Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA) and Sanofi SA (NASDAQ:SNY) presented new, detailed results from the RELIEVE ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report), with a price ...

In February 2025, Teva Pharmaceuticals and Alvotech announced the U.S. launch of SELARSDI™ (ustekinumab-aekn), a biosimilar to Stelara® (ustekinumab), following FDA approval and a provisional ...

The U.S. Food and Drug Administration (FDA) has approved SELARSDI™ (ustekinumab-aekn), a biosimilar to Stelara® (ustekinumab), for treating various conditions including plaque psoriasis ...

Regulatory ApprovalFormycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® 25.02.2025 / 06:30 CET/CESTThe issuer is solely ...

On Monday, Axsome Therapeutics, Inc. (NASDAQ:AXSM) signed a settlement agreement with Teva Pharmaceuticals Inc ... This pharma stock has made strong gains over the past 12 months thanks to ...

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.

(Reuters) - Johnson & Johnson (NYSE: JNJ) said on Monday it had filed a lawsuit against Samsung (KS: 005930) Bioepis for breaching its contract agreement with the drugmaker over the launch of a ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDItm for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination ...